Presentation is loading. Please wait.

Presentation is loading. Please wait.

Prevalence of depression severity according to the stage of diabetic nephropathy. Prevalence of depression severity according to the stage of diabetic.

Published byRéka Hegedűsné Modified over 5 years ago

Similar presentations

Presentation on theme: "Prevalence of depression severity according to the stage of diabetic nephropathy. Prevalence of depression severity according to the stage of diabetic."— Presentation transcript:

1 Prevalence of depression severity according to the stage of diabetic nephropathy.
Prevalence of depression severity according to the stage of diabetic nephropathy. The white bar shows both the number and proportion of participants who had total PHQ-9 scores of 0–4 points (no depression), the gray bar shows those who had 5–9 points (mild depression), and the black bar shows those who had 10 points or more (moderate or severe depression) in stages 1–5 undergoing dialysis and stage 5 undergoing kidney transplantation, respectively. PHQ-9, Patient Health Questionnaire-9. Keiko Takasaki et al. BMJ Open Diab Res Care 2016;4:e000310 ©2016 by American Diabetes Association

Download ppt "Prevalence of depression severity according to the stage of diabetic nephropathy. Prevalence of depression severity according to the stage of diabetic."

Similar presentations

Identification of depression in diabetes: the efficacy of PHQ-9 and HADS-D by Prasuna Reddy, Benjamin Philpot, Dale Ford, and James A Dunbar BJGP Volume.

Identification of depression in diabetes: the efficacy of PHQ-9 and HADS-D by Prasuna Reddy, Benjamin Philpot, Dale Ford, and James A Dunbar BJGP Volume.
Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.
The prevalence of diabetes (A), impaired glucose tolerance (B), impaired fasting glucose (C), and impaired glucose metabolism (D) among those with Finnish.

The prevalence of diabetes (A), impaired glucose tolerance (B), impaired fasting glucose (C), and impaired glucose metabolism (D) among those with Finnish.
Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.

Distribution of the absolute percentage differences of each basal rate estimate to final basal rates. Distribution of the absolute percentage differences.
Comorbidity status in patients with CKD stage 4 or 5 not on dialysis, peritoneal dialysis, haemodialysis and transplanted patients (bars), as well as in.

Comorbidity status in patients with CKD stage 4 or 5 not on dialysis, peritoneal dialysis, haemodialysis and transplanted patients (bars), as well as in.
Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.

Frequency of potential risk of hypoglycemia for each estimate method, defined as a percentage difference between the estimate and final basal rate. Frequency.
Subgroup analysis: random-effects model of the risk of lower extremity amputation in people with diabetes associated with depression compared with no depression.

Subgroup analysis: random-effects model of the risk of lower extremity amputation in people with diabetes associated with depression compared with no depression.
The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)

The excess effect of 3 or 6 months low to moderate carbohydrate diet compared with high-carbohydrate diet on HbA1c (%) versus reported intake (Energy %)
Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.

Distribution of the percentage differences of each basal rate estimate to final basal insulin rates. Distribution of the percentage differences of each.
The worldwide association between mean annual temperature and age-adjusted, sex-adjusted, income-adjusted and obesity-adjusted prevalence of raised fasting.

The worldwide association between mean annual temperature and age-adjusted, sex-adjusted, income-adjusted and obesity-adjusted prevalence of raised fasting.
Obesity and type 2 diabetes forecasts.

Obesity and type 2 diabetes forecasts.
The association between mean annual temperature and diabetes incidence in the USA over the period 1996–2009. The association between mean annual temperature.

The association between mean annual temperature and diabetes incidence in the USA over the period 1996–2009. The association between mean annual temperature.
Muscle quality (mean±SE, %) of the patients with NDR, NPDR and PDR

Muscle quality (mean±SE, %) of the patients with NDR, NPDR and PDR
(A) Body weight (g). (A) Body weight (g). T2DM: n=6 per group. *p

(A) Body weight (g). (A) Body weight (g). T2DM: n=6 per group. *p
Kaplan–Meier estimates of the incidence of first heart failure hospitalization during follow-up according to the statin category among patients with type.

Kaplan–Meier estimates of the incidence of first heart failure hospitalization during follow-up according to the statin category among patients with type.
Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.

Correlation of E/e’ with age (A), gender (B), fasting insulin (C), and sulfonylurea use (SU) (D) among patients with type 2 diabetes mellitus. Correlation.
Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.

Cumulative incidence of (A) ESRD, (B) all-cause death, (C) all-cause death without ESRD and (D) ESRD or all-cause death in patients with T1DM diagnosed.
Proportion of participants with type 2 diabetes (diabetes categories are defined according to the American Diabetes Association 2010 Diagnostic Guidelines),

Proportion of participants with type 2 diabetes (diabetes categories are defined according to the American Diabetes Association 2010 Diagnostic Guidelines),
Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.

Subgroup analysis. Subgroup analysis. Effect of vitamin D supplementation on outcome variables in subgroups defined by baseline levels of the respective.
Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.

Gender differences in diabetes prevalence in 2009 in the general Portuguese population patients and in patients with CAP. Diabetes prevalence is higher.

Similar presentations

Ads by Google